These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8819224)

  • 41. Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon?
    Narciso-Schiavon JL; Freire FC; Suarez MM; Ferrari MV; Scanhola GQ; Schiavon Lde L; Carvalho Filho RJ; Ferraz ML; Silva AE
    Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):350-6. PubMed ID: 20611005
    [TBL] [Abstract][Full Text] [Related]  

  • 42. alpha-Interferon retreatment of patients with chronic hepatitis C.
    Rabinovitz M; Block G; Finkelstein SD
    Am J Gastroenterol; 1996 Aug; 91(8):1523-6. PubMed ID: 8759654
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interferon-alpha suppresses liver cell proliferation in patients with chronic hepatitis C virus infection.
    Donato MF; Degott C; Arosio E; Martinot M; Monti V; Morabito A; Marcellin P; Colombo M
    J Viral Hepat; 2005 Sep; 12(5):499-506. PubMed ID: 16108765
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recombinant alpha 2B interferon (IFN) in the treatment of chronic hepatitis C disease in thalassaemia major (TM).
    Wonke B; Donohue SM; Hoffbrand AV; Scheuer PJ; Brown D; Dusheiko G
    Bone Marrow Transplant; 1993; 12 Suppl 1():24-5. PubMed ID: 8397033
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN.
    Milella M; Antonelli G; Santantonio T; Giannelli G; Currenti M; Monno L; Turriziani O; Pastore G; Dianzani F
    Hepatogastroenterology; 1995 Jul; 42(3):201-4. PubMed ID: 7590565
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients.
    Boucher E; Jouanolle H; Andre P; Ruffault A; Guyader D; Moirand R; Turlin B; Jacquelinet C; Brissot P; Deugnier Y
    Hepatology; 1995 Feb; 21(2):322-7. PubMed ID: 7843700
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term variations of serum laminin and procollagen III peptide in chronic HCV hepatitis after alpha-interferon therapy.
    Casaril M; Capra F; Gabrielli GB; Tognella P; Rizzi A; Squarzoni S; De Maria E; Colombari R; De Sandre G; Corrocher R
    Ital J Gastroenterol; 1996 Jan; 28(1):15-9. PubMed ID: 8743068
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C.
    Giannelli G; Antonelli G; Fera G; Del Vecchio S; Riva E; Broccia C; Schiraldi O; Dianzani F
    Clin Exp Immunol; 1994 Jul; 97(1):4-9. PubMed ID: 8033418
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Parameters predicting response to alpha-interferon treatment in chronic hepatitis C.
    Glück T; Seelig R; Dette S; Bühring HJ; Renz M; Kwon S; Wiedmann KH; Weber P
    Hepatogastroenterology; 1997; 44(14):484-91. PubMed ID: 9164523
    [TBL] [Abstract][Full Text] [Related]  

  • 50. alpha-Interferon treatment of chronic hepatitis C in young patients with homozygous beta-thalassemia.
    Di Marco V; Lo Iacono O; Capra M; Grutta S; Ciaccio C; Gerardi C; Maggio A; Renda D; Almasio P; Pisa R
    Haematologica; 1992; 77(6):502-6. PubMed ID: 1289187
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Appropriate interferon-alpha therapy for chronic hepatitis C: an assessment by quantitative changes in serum hepatitis C virus-RNA.
    Watanabe S; Kobayashi Y; Konishi M; Yokoi M; Kakehashi R; Kaito M; Suzuki S
    Intern Med; 1993 Jul; 32(7):523-9. PubMed ID: 8286827
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study.
    Villa E; Trande P; Grottola A; Buttafoco P; Rebecchi AM; Stroffolini T; Callea F; Merighi A; Camellini L; Zoboli P; Cosenza R; Miglioli L; Loria P; Iori R; Carulli N; Manenti F
    Dig Dis Sci; 1996 Jun; 41(6):1241-7. PubMed ID: 8654159
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis.
    Bresci G; Del Corso L; Romanelli AM; Giuliano G; Pentimone F
    J Am Geriatr Soc; 1993 Aug; 41(8):857-62. PubMed ID: 7688007
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.
    Nishiguchi S; Kuroki T; Nakatani S; Morimoto H; Takeda T; Nakajima S; Shiomi S; Seki S; Kobayashi K; Otani S
    Lancet; 1995 Oct; 346(8982):1051-5. PubMed ID: 7564784
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Changes of serum hepatitis C virus levels in patients with chronic hepatitis C treated with two courses of interferon administration.
    Saitoh Y; Miura M; Niitsuma H; Numata N; Ohori H; Ishii M; Toyota T
    Tohoku J Exp Med; 1994 Aug; 173(4):361-9. PubMed ID: 7529950
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The breakthrough phenomenon during alpha-interferon therapy of chronic hepatitis C: incidence, management, and outcome.
    Lebovics E; Lantin J; Chaurushia G; Dworkin BM; Casellas A; Rosenthal WS
    Am J Gastroenterol; 1995 Jun; 90(6):951-4. PubMed ID: 7771428
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Autoantibodies in children with chronic hepatitis B infection and the influence of interferon alpha.
    Kansu A; Kuloğlu Z; Demirçeken F; Girgin N
    Turk J Gastroenterol; 2004 Dec; 15(4):213-8. PubMed ID: 16249973
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: a pilot study.
    Gatselis NK; Georgiadou SP; Tassopoulos N; Zachou K; Liaskos C; Hatzakis A; Dalekos GN
    World J Gastroenterol; 2005 Jan; 11(4):482-7. PubMed ID: 15641130
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Prognostic relevance of hepatitis C virus genotype for responsiveness to interferon-alpha].
    Berg T; König V; Küther S; Heuft HG; Wittmann G; Lobeck H; Hopf U
    Z Gastroenterol; 1995 Aug; 33(8):426-30. PubMed ID: 7483733
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cryoglobulinemia in hepatitis C virus chronic active hepatitis: effects of interferon-alpha therapy.
    Casaril M; Capra F; Gabrielli GB; Bassi A; Squarzoni S; Dagradi R; De Maria E; Corrocher R
    J Interferon Cytokine Res; 1996 Aug; 16(8):585-8. PubMed ID: 8877728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.